AHWhite on Nostr: Quite impressive phase 3 data from Summit's new lung cancer drug: ...
Quite impressive phase 3 data from Summit's new lung cancer drug:
https://www.biopharmadive.com/news/summit-wclc-ivonescimab-keytruda-full-results-lung-cancer/726376/
For context, "Keytruda" has been pretty much the gold-standard for a decade now for this indication and has back then revolutionized the immune-oncology field. To now have a new potential drug that performs "twice as good" is really something.
A drawback is that this is based on clinical data from China and there have been some problems in the past with reliability here. But on the other hand, this effect is so huge, they would have really needed to mess up the trial or tinker with the data for this to be not true.
#science #cancer #oncology #drugs
https://www.biopharmadive.com/news/summit-wclc-ivonescimab-keytruda-full-results-lung-cancer/726376/
For context, "Keytruda" has been pretty much the gold-standard for a decade now for this indication and has back then revolutionized the immune-oncology field. To now have a new potential drug that performs "twice as good" is really something.
A drawback is that this is based on clinical data from China and there have been some problems in the past with reliability here. But on the other hand, this effect is so huge, they would have really needed to mess up the trial or tinker with the data for this to be not true.
#science #cancer #oncology #drugs